Keith C. Kummerfeld CPA Net Worth

The estimated Net Worth of Keith C Kummerfeld is at least $166 Mille dollars as of 14 July 2023. Mr Kummerfeld owns over 6,968 units of Arcturus Therapeutics Inc stock worth over $166,120 and over the last 6 years he sold ARCT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr CPA ARCT stock SEC Form 4 insiders trading

Mr has made over 4 trades of the Arcturus Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 6,968 units of ARCT stock worth $62,433 on 14 July 2023.

The largest trade he's ever made was exercising 6,968 units of Arcturus Therapeutics Inc stock on 14 July 2023 worth over $62,433. On average, Mr trades about 1,489 units every 140 days since 2019. As of 14 July 2023 he still owns at least 7,918 units of Arcturus Therapeutics Inc stock.

You can see the complete history of Mr Kummerfeld stock trades at the bottom of the page.

Mr. Keith C. Kummerfeld CPA biography

Keith C. Kummerfeld CPA is the VP of Fin. & Corp. Controller at Arcturus Therapeutics Inc.

What's Mr CPA's mailing address?

Keith's mailing address filed with the SEC is C/O ARCTURUS THERAPEUTICS HOLDINGS INC., 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO, CA, 92121.

Insiders trading at Arcturus Therapeutics Inc

Over the last 12 years, insiders at Arcturus Therapeutics Inc have traded over $137,035,874 worth of Arcturus Therapeutics Inc stock and bought 56,234 units worth $767,374 . The most active insiders traders include William M Kahane, Nicholas S Schorsch e Peter C Farrell. On average, Arcturus Therapeutics Inc executives and independent directors trade stock every 33 days with the average trade being worth of $1,034,818. The most recent stock trade was executed by Jing L. Marantz on 14 June 2024, trading 3,131 units of ARCT stock currently worth $65,688.

What does Arcturus Therapeutics Inc do?

founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.

Complete history of Mr Kummerfeld stock trades at Arcturus Therapeutics Inc

Arcturus Therapeutics Inc executives and stock owners

Arcturus Therapeutics Inc executives and other stock owners filed with the SEC include:

• Andrew Sassine,
  Chief Financial Officer, Director
• Joseph Payne,
  President, Chief Executive Officer, Director
• Joseph E. Payne M.Sc.,
  Founder, Pres, CEO & Director
• Dr. Steven George Hughes M.B.A., M.D.,
  Chief Medical Officer
• Dr. Padmanabh Chivukula,
  Founder, Chief Scientific Officer, COO & Sec.
• Andrew H. Sassine,
  CFO & Director
• Padmanabh Chivukula,
  Chief Operating Officer, Chief Scientific Officer
• Lance Kurata,
  Chief Legal Officer
• Karah Parschauer,
  Director
• Edward Holmes,
  Independent Director
• Peter Farrell,
  Independent Chairman of the Board
• Magda Marquet,
  Independent Director
• James Barlow,
  Independent Director
• Steven Hughes,
  Chief Development Officer
• Dr. Nirdosh Jagota Ph.D.,
  Exec. VP & Chief Regulatory Officer
• Kevin T. Skol,
  Sr. VP of Bus. Devel. & Alliance Management
• Neda Safarzadeh,
  Sr. Director and Head of Investor Relations/PR & Marketing
• Dr. Dushyant B. Varshney Ph.D.,
  Exec. VP & Chief Technology Officer
• Keith C. Kummerfeld CPA,
  VP of Fin. & Corp. Controller
• Capital Group, Lpluxor Capi...,
  
• William G Stanley,
  Director
• Leslie D Michelson,
  Director
• Susan E Manning,
  See Remarks
• William M Kahane,
  President and CEO
• Brian D Jones,
  CFO and Treasurer
• Nicholas S Schorsch,
  Director
• Robert Burns,
  Director
• Pad Chivukula,
  Chief Scientific Officer & COO
• Keith C Kummerfeld,
  See Remarks
• Andy Sassine,
  Chief Financial Officer
• Lance Kurata,
  Chief Legal Officer
• Pharmaceutical Inc. Ultragenyx,
  Director
• Jing L. Marantz,
  Director
• John Markels,
  Director
• Moncef Slaoui,
  Director